# bioAffinity Technologies Receives Japanese Patent Allowance for AI-Powered Lung Cancer Test

- URL: https://stocks.freetheai.org/news/bioaffinity-technologies-receives-japanese-patent-allowance-for-ai-powered-lung-05940a
- Published: 2026-10-08T12:33:04Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:BIAF](https://stocks.freetheai.org/symbols/NASDAQ-BIAF)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

bioAffinity Technologies, Inc. (NASDAQ:BIAF) has received a Notice of Allowance from the Japan Patent Office for its CyPath Lung artificial intelligence-powered method. The technology is designed to predict early-stage lung cancer. The patent will officially be issued once the company pays the required registration fee, marking the first patent in Japan for CyPath Lung that utilizes an AI-built algorithm.

This approval strengthens the company's intellectual property protection in key global markets. The new patent adds to a growing portfolio that already includes 22 awarded patents in the United States and other international jurisdictions, along with 36 pending applications. This also marks the fifth patent awarded in Asia for the company's early-stage lung cancer testing technology, which has previously received patent protections in China and Hong Kong.

Investors will likely monitor the official issuance of the patent following the fee payment and any subsequent commercialization efforts for CyPath Lung in the Japanese market. Shares of bioAffinity Technologies, Inc. rose 1.65% to 6.16 USD today following the announcement.

## Key points

- bioAffinity Technologies received a Japanese patent allowance for its AI-powered CyPath Lung test.
- The patent will be the company's first in Japan to protect an AI-built algorithm for lung cancer prediction.
- The allowance increases the company's global intellectual property portfolio to 23 awarded patents once issued.
- This is the fifth patent awarded to the company in Asia, joining existing protections in China and Hong Kong.

## Questions and answers

### What is the new patent received by bioAffinity Technologies?

The company received a Notice of Allowance from the Japan Patent Office for its CyPath Lung technology, which uses an artificial intelligence-powered algorithm to predict early-stage lung cancer.

### How many patents does bioAffinity Technologies hold?

Once the Japanese patent is officially issued, it will join a global portfolio of 22 already awarded patents and 36 pending applications.

### Where else in Asia does bioAffinity Technologies have patent protection?

The Japanese patent represents the company's fifth patent in Asia, alongside existing patent protections for its early lung cancer test in China and Hong Kong.